What did ArborGen Holdings Limited announce?
ArborGen Holdings Limited (NZX: ARB) filed “ArborGen Holdings Annual Shareholder Meeting” with NZX on 14 September 2026, as an agm announcement.
From the announcement:“CHAIR’S ADDRESS – DAVE KNOTT I want to use my address to talk directly about where ArborGen stands today, the progress we have made, what comes next and other matters that we know are important to shareholders.”
- Which company?
- ArborGen Holdings Limited (NZX: ARB)
- When was it filed?
- 14 September 2026
- Where is the original?
- NZX announcement
ArborGen Holdings Annual Shareholder Meeting
1
2026 ANNUAL SHAREHOLDERS’ MEETING SPEECHES
1. WELCOME
Good morning and welcome to ArborGen’s annual shareholders meeting. I am Dave
Knott, Chairman of the Board.
It’s great to be back in New Zealand to meet shareholders and talk about ArborGen’s
performance. Thank you for joining us today.
2. CHAIR’S ADDRESS – DAVE KNOTT
I want to use my address to talk directly about where ArborGen stands today, the
progress we have made, what comes next and other matters that we know are
important to shareholders.
There is much about ArborGen that gives us confidence. We have strong market
positions, valuable intellectual property and genetics, long-standing customer
relationships, and a growing business in Brazil with significant long-term potential.
However, our overall performance is not yet where we hoped it would be and we
recognise that the shareholder experience has been disappointing.
In particular, our share price remains at a level that none of us are satisfied with, and
low liquidity in ArborGen shares is a genuine concern for some shareholders.
As a Board, we are very conscious that ultimately we need to demonstrate the value
within ArborGen through stronger performance and better returns.
3. REGIONAL MARKET LOOKBACK
It’s worth looking back at our market development since the sale of our Australia and
New Zealand business in FY22, following which we focused our resources on our two
core markets, the US South and Brazil. Since then, those markets have followed quite
different paths.
Brazil
In Brazil, we moved quickly to build scale in a large and growing forestry market.
Revenue increased from around $8 million in FY22 to approximately $30 million by
FY26, growing from 16% to more than 40% of our Group revenue. Over that period, we
acquired and leased additional nurseries, expanded production and increased total
capacity to more than 135 million seedlings annually, including contract growers.
2
That rapid expansion also created challenges. Systems, processes and financial
disciplines did not always develop at the same pace as the business, while drought-
related production constraints in recent years affected yields and increased costs.
Our focus has therefore shifted from building scale to consolidating what we have built.
We have strengthened the team, financial processes and production planning; are
shifting sales to higher-value protected clones, and are focused on improving yields and
productivity. This is an ongoing process with improvement initiatives still underway.
US South
The US has followed a different path.
In FY22, the business was performing strongly, with record advanced genetics sales. We
continued to invest in higher-value MCP genetics, container capacity and our nursery
network.
However, weaker housing construction, reduced timber harvesting and the structural
decline in pulp demand progressively reduced seedling demand. What initially appeared
cyclical has developed into a more fundamental change in the market.
We have responded by reducing costs and right-sizing the footprint, including nursery
rationalisation and the sale of non-core operations – a process that is ongoing this year.
At the same time, we continue to invest behind our key competitive advantage:
advanced genetics. In a market increasingly focused on higher-value sawtimber, we
believe the ability to grow better-performing trees remains highly relevant.
4. FY26 PERFORMANCE SNAPSHOT
In FY26, we delivered a result ahead of revised guidance and within the range originally
set.
Revenue was a record result, despite the weak US market. Earnings and margin also
recovered year on year.
This was supported by increasing average sales prices as our strategy to move
customers to higher value products bears fruit. This remains one of our strategic
priorities.
5. MARGIN STORY
Margins have moved around as the business has grown and market conditions have
changed.
In Brazil, rapid expansion has brought significant revenue growth, but also the costs of
building capacity, integrating new operations and addressing production and process
challenges.
In the US, lower volumes have reduced utilisation of our nursery network and increased
the impact of fixed costs.
3
At the same time, we have continued to invest in higher-value products - advanced
genetics and containerised seedlings – and this remains an important driver of margin
over the longer term.
Our focus now is on building revenue, reducing costs and converting the scale and
capability we have built into stronger returns.
6. CASH GENERATION AND DEBT REDUCTION
That focus on stronger returns also needs to translate into improved cash generation.
Over recent years, we have invested significantly in building ArborGen’s growth
platform, particularly in Brazil, while challenging conditions in the US have constrained
earnings and cash flow. As a result, debt is higher than we would like.
Our priorities are now changing. With much of the investment required to establish the
Brazil platform behind us, we are increasingly focused on generating more cash from
the assets and capacity already in place.
That means disciplined capital expenditure, tighter working capital management,
improved margins and productivity, and continuing to review our asset base for
opportunities to release capital.
Reducing debt is a clear priority for the Board. Stronger operating cash flow, together
with proceeds from the divestment of surplus or non-core assets where appropriate,
will be directed towards deleveraging. The sale of the Ridgeville building has reduced
debt by US$8.6m, with a flow-on benefit from lower interest costs this year.
This is an important part of the next phase for ArborGen: translating earnings growth
into cash, strengthening the balance sheet and creating greater flexibility for the future.
7. SHAREHOLDER VALUE
We recognise that shareholders have heard us talk about ArborGen’s potential for some
time. Our priority now is to convert that potential into stronger earnings, cash flow and
returns.
There is no single initiative that will achieve this. It requires continued profitable growth
in Brazil, improving the performance and cost structure of the US business, and
disciplined capital allocation. Importantly, growth needs to create value, not simply add
scale.
Some shareholders have asked whether ArborGen should undertake another strategic
review, particularly given the performance of our share price.
Our last review in 2021 followed an unsolicited approach to acquire the company.
Rather than simply reject an offer we believed materially undervalued ArborGen, we
appointed PwC to test a broad range of alternatives, including asset and company sales
and a potential US listing.
That process resulted in the sale of our Australian and New Zealand operations for
NZ$22.25 million. However, the proposals received for the wider business did not
represent better value than retaining and investing in the US and Brazil.
4
Much has changed since then. The US market has undergone a significant structural
reset, while Brazil has developed into an important growth business.
We do not believe another formal review simply for the sake of undertaking a process is
necessarily the answer. But we are not closed to alternatives.
The Board continues to assess our portfolio, capital allocation and opportunities to
realise greater value.
Our objective is not to preserve ArborGen in its current form. It is to maximise value for
all shareholders.
Share price and liquidity
I also want to address our share price and liquidity.
ArborGen has a relatively limited free float – around 50% of issued capital - and low
trading volumes.
The Board has acted where appropriate and our 2024 share buyback resulted in
approximately 5.9 million shares being acquired and cancelled.
We cannot determine the price at which our shares trade, but we can improve the
performance of the business and allocate capital carefully.
Ultimately we believe that stronger financial performance is the most sustainable way
to create shareholder value.
Leadership transition
As shareholders may know, Justin Birch recently resigned as Chief Executive after three
years with ArborGen.
On behalf of the Board, I acknowledge Justin’s contribution. His departure also provides
an opportunity to consider the leadership ArborGen needs for its next phase.
We are also aware of shareholder interest in the equity arrangements put in place when
Justin was appointed. Tenure-based restricted shares – a common remuneration
practice in the US -vested in accordance with the terms approved at the time.
Performance-based shares under the long-term incentive plan were not awarded as the
targets were not met.
The Board recognises that executive remuneration is judged alongside company
performance and shareholder returns.
For future leadership, we will ensure executive reward is clearly aligned with sustained
performance, delivery against our strategic priorities and long-term shareholder value.
8. STRATEGIC PROGRESS AND NEXT STEPS
The next phase for ArborGen is about execution. I have talked about our three priorities
for this year.
We have a strong position in the US South, notwithstanding the structural challenges
facing that market, and an increasingly valuable growth platform in Brazil.
5
Our task is to make more of those positions.
In Brazil, that means consolidating and integrating our operations following a period of
rapid expansion, capturing the growth available to us and continuing to increase the
contribution from higher-value protected clones.
In the US, it means ensuring the business is configured appropriately for a structurally
smaller market, while continuing to upsell our customers to the higher quality advanced
genetics that differentiate ArborGen.
We need to expand our margins – firstly by growing sales of higher value products, but
also by improving our focus on commercial and operational excellence and optimising
our existing assets.
Across the Group, we need to generate stronger cash flow, drive profit and be
disciplined about where we invest.
We will also continue to challenge our assumptions about the business and remain
open to opportunities that could deliver greater value.
9.
FY27 OUTLOOK
For FY27, we are targeting a continued improvement in revenue, cash generation and
debt reduction. This will be driven by continued volume growth in Brazil, some revenue
growth in the US, further improvements in operating leverage, and continued
investment in advanced products.
We are not providing guidance at this time, but will look to do so with the half year
results in November.
10. LOOKING AHEAD
I recognise that shareholders, particularly those who have been with ArborGen for
many years, want to see tangible evidence of progress.
That is a reasonable expectation and one which the Board shares. We are shareholders
too, and our interests are aligned in wanting ArborGen's underlying value to be
reflected in the returns delivered to all shareholders.
We believe ArborGen has valuable assets, strong market positions and a genuine
growth opportunity in Brazil. Our priority is to convert those strengths into improved
earnings, cash generation and, ultimately, better returns for shareholders.
It’s important to remember the timelines that we are working with. Our customers are
planting for forests they won’t harvest for 25 years or more.
In today’s market, where volumes are constrained, the path to earnings resilience is
through quality. While they may be planting less, our customers are increasingly
planting higher quality seedlings – an area in which we excel.
As VP of Product Development, interim Chief Executive Patrick Cumbie has played an
essential role in building ArborGen’s leadership position in advanced genetics. I’ll now
hand over to him to talk to you about our product portfolio and the position of strength
it gives us in the market.
6
11. INTERIM CEO’S INTRODUCTION
Good morning. It’s good to be here with you today as we talk about ArborGen, both the
past year and looking forward.
As you are all aware this is a season of leadership transition for the company. I am
grateful for the opportunity to serve the ArborGen team in this interim role.
I have been in the industry for 24 years and with ArborGen for over 16, starting as a
project scientist focused on biotechnology projects and then shifting over the years to
manage and lead all of the pine development efforts before moving to senior
management.
Forest genetics is a passion and I’m excited to help lead the company through this
time so we can continue to provide superior genetics to the market, educate the
market on the value proposition, and provide excellent quality and service to our
customers and partners.
Working on Product Development has given me a unique opportunity to be connected
both to our sales team to support partners and customers, but also very much
integrated into our operations team through orchard strategy, genetic deployment,
and quality assurance.
We are poised to move forward to successfully execute our strategy of higher adoption
of MCP in the US, and in Brazil both advanced families of pine and protected clones of
eucalyptus.
12. LEADERSHIP FOCUS 2026
As Dave has said, we have three strategic priorities this year – to build sales of high
value products, expand our margins, and generate cash to support profit and debt
reduction.
The management team have identified four critical areas to help us be
successful. These are not a departure from our previous focus, but represent
a streamlining of what is essential, providing a clear focus for our team.
Firstly, people and culture ... we have no hope of achieving operational or financial
success without a committed group. As mentioned in years past, we have been working
to put the right people into leadership as well as technical and operational roles.
The long-term nature of our industry and our business also means we need a team who
is committed to the mission of the company. Especially in a time of transition, we are
focusing on strengthening our culture to make sure we put our best foot forward in
achieving sales, production, and quality goals. The combined experience, talent and
institutional knowledge across our two regions is something our competitors can’t
replicate overnight.
7
Next is genetics leadership: Our genetic resources in the US are a tremendous asset.
We will continue to produce the best loblolly pine seedlings available in the market,
invest in product development efforts to prepare the next generation of trees, orchards,
seeds, and products going out to customers. This past year we refreshed our pine
products which I’ll talk about today.
In Brazil the supply of US pine genetics continues to be in demand, and the protected
clones of eucalyptus will be the focus as we work to also develop our own proprietary
clones for the market.
Third is Operational Excellence: As the market headwinds continue to be a challenge in
the US, it is imperative to make necessary adjustments to reduce costs and we’re
looking closely at how, where and what we grow.
In Brazil, we significantly expanded our production capacity over the last two years with
the nursery acquisitions and new partnerships. Now it is time to make them “one
company” as we work to align operating efficiency and management of different
facilities.
Finally, financial stability: We have invested heavily in expanding our US container
product and nursery capacity in Brazil. Our focus now is on maximising the value of
those investments to generate cash, reduce net debt, and increase our ability to make
measured investments for growth in both geographies.
13. THE ‘GENETICS DIVIDEND’
Having worked in Product Development for over 16 years, I wanted to share my
thoughts on ArborGen’s products and offer and what gives us such a strong position in
the market.
Growers are making decisions today that won’t deliver payback for another 25 years.
The seedlings they put in the ground shape growth, form, wood properties, health and
survival - then compound across time, hectares and harvest decisions, influencing
everything from thinning options to log mix at final harvest.
That’s the genetics dividend: an important upfront choice that can deliver outsized,
long-term returns.
Genetics has been recognised in the US for loblolly pine for decades, but
understanding and confirming the value creation with mature stands has been lacking.
We are now getting very positive feedback from customers who invested in MCP® 10 to
15 years ago and are thinning the plantations. One customer has invested significantly
to assess the difference between OP and MCP genetics in operational plantations, and
we are excited to see that operational data confirms and reinforces the value
proposition in MCP.
Traditionally, growers have had access to pulp markets which provided a mid-rotation
cash flow from thinnings. This often drove the decision on how many trees
per hectare to plant. With the loss of these markets in some areas, growers
are considering planting fewer trees.
8
For many, it’s not a dramatic reduction although some growers are looking to
make larger decreases. This could impact the overall market size, but will also
drive growers towards better, more advanced genetics. In essence, with fewer trees per
hectare planted, the success of each tree planted becomes more important.
Growers need every tree to have a high probability of producing sawtimber. Where
traditional Open-pollinated families might produce stems with 40-60% quality stems,
MCP offers 75-85% quality stems, a much better option when you reduce your planting
densities by 15-25%.
14. SMARTER SEEDLINGS. CLEARER CHOICES
This past year in the US, we refreshed our pine product categories with clear brand tiers
for our MCP pine seedlings. Building on a decade of testing across the Southeast and
deeper integration of proprietary and cooperative data, the team developed the AG
Score, a single index that evaluates families in each region based on the traits that
most impact plantation success. Each tier is designed to make seedling selection easier
and highlight tangible performance benefits.
We’ve had positive feedback from customers on the rebranding and the data driven
approach. Value creation is about growing more tons of wood that will qualify as
sawtimber rather than pulpwood. The AG score index and refreshed product categories
help customers understand the opportunity that comes with selecting higher
performing genetic products.
15. CUSTOMERS REALISING SIGNIFICANT GAINS
We are seeing real-world forest plantations planted with MCP Pro+ seedlings showing
significant growth improvements over OP seedlings, and the sawtimber at harvest is
projected to be more than double that of OP due to improvements in yield and quality.
16. EUCALYPTUS
In Brazil, we continue to focus on producing protected clones that are licensed from
other companies.
However, our product development team is working to bring ArborGen clones to the
market, including testing the clones across multiple regions to identify which perform
the best in a specific geography.
17. MARKET OPPORTUNITY
Our advantage is the combination of a sustained decades-long research and
development programme, rigorous field testing and data capture, and the operational
ability to commercialise winning genetics at scale.
Our strategy is designed to grow the adoption of advanced genetics while strengthening
the operating foundation that allows us to deliver performance, consistency and service
at scale.
9
We are intentionally focused on markets where the combination of scale, long-term
planting demand and customer sophistication makes advanced genetics most valuable.
The market opportunities in Brazil remain compelling and we are well positioned to
convert those into sustained earnings growth. While the US South is more challenging,
we remain one of the leading suppliers of advanced genetics seedlings in the market.
The emerging carbon forestry market also presents a meaningful long term opportunity,
and we are already partnering with carbon developers and co-hosting industry events
that position ArborGen at the centre of this conversation.
Thank you.
---
1
ANNUAL
SHAREHOLDERS’ MEETING
15 September 2026
ArborGen 2026 ASM
INTRODUCING
THE BOARD
2
David Knott – Chairman
Appointed 19 August 2021
George Adams – Independent Director
Appointed 12 August 2019
Standing for re-election
Paul Smart – Independent Director
Appointed 21 August 2018
Standing for re-election
Unanimously supported by the Board
Thomas Avery – Independent Director
Appointed 18 July 2018
Standing for re-election
Unanimously supported by the Board
Ozey Horton – Independent Director
Appointed 11 July 2018
ArborGen 2026 ASM
David Knott
CHAIR OF THE BOARD
ArborGen 2026 ASM
LOOKBACK REGIONAL MARKETS
0
10
20
30
40
50
60
70
80
FY22FY23FY24FY25FY26
Sales Revenue
US $m
BrazilUS South
Sale of ANZ business in FY22 → focus on US South and
Brazil
Brazil
•Rapid expansion, growing pains now being addressed
•Opportunity: Large and growing market with
increasing demand for higher quality seedlings
US South
•Market steadily weakened → structural downturn
•Opportunity: Focus on higher value vs volume
ArborGen 2026 ASM
4
FY26 PERFORMANCE SNAPSHOT
10.1
9.2
12.8
8.8
11.5
FY22FY23FY24FY25FY26
Adjusted US GAAP EBITDA
US $m
47.5
56.1
67.7
63.2
68.2
360m
375m
369m
328m
324m
FY22FY23FY24FY25FY26
Sales Volume and Revenue
US $m
Sales RevenueSales Volumes
•Record revenue result – supported by higher
average selling prices
•Adjusted US GAAP EBITDA up 31% YOY, despite
weakness in US market
•Earnings increased ahead of revenue – driven
by revenue growth, pricing, mix and cost
efficiencies translating into higher operating
earnings
Strategic priority: High-value sales mix
ArborGen 2026 ASM
5
MARGINS REFLECT GROWTH AND MARKET CYCLE
Growth investments made → platform for significant operating leverage
34
35
38
33
33
FY22FY23FY24FY25FY26
Gross Margin % (US GAAP)
FY22 – FY26: Investment into growth opportunity in Brazil
FY26 margins reflect:
•Lower US volumes + under-utilised capacity
•Brazil scaling costs + labour/input inflation
•Some pricing pressure on market-clones in Brazil
Next step to convert recent investment into stronger
margins through increasing sales and lower costs
Strategic priority: Margin expansion
Investment in growth initiatives
ArborGen 2026 ASM
6
CAPITAL MANAGEMENT
Increase in borrowings reflects investment in growth
FY22 – 26: Invested substantially to grow the business
– expansion of production capacity in Brazil, higher
value genetics, container seedlings
Actions taken to improve cash flow and reduce debt:
•Capex reduced to $4.1m in FY26 (FY25: $7.7m)
•Right sizing US business – people, footprint
•Sale of non-core assets and property to release
capital: Ridgeville HQ in July 2026 - net proceeds of
$8.8m used to pay down debt
Strategic priority: Cash generation and debt
reduction
-1.5
-1.4
-6.5
-4.3
11.5
13.0
14.4
20.9
25.2
FY22FY23FY24FY25FY26
Net Debt and Cash Generation
Investment in growth
Net debt
post-HQ sale
ArborGen 2026 ASM
7
SHAREHOLDER VALUE
8
Maximise value for all shareholders
•Focus on converting potential into stronger earnings, cash flow and returns
•Continue to assess portfolio, capital allocation and opportunities to realise greater value
•Remain open to strategic proposals
Share price and liquidity
•Challenge: Limited free float → small trades have disproportionate impact on share price
•Lack of visibility and institutional support for micro-cap stocks
•Stronger financial performance is the most sustainable way to create shareholder value
8
ArborGen 2026 ASM
STRATEGIC PROGRESS AND NEXT STEPS
9
FY22 – FY25
Reshape and Invest for Growth
FY26 – FY27
Strengthen
FY28 onwards
Extract Value
✓Sale of ANZ
✓Exit out of pandemic
disruption
✓Rapidly scaled Brazil
✓Increasing shift towards
higher-value genetics
✓Navigated prolonged
cyclical downturn in US
✓Improvements to the
operating platform
✓Building supply resilience
•High value sales mix: accelerate
sales, adoption and development of
advanced products
•Margin expansion: continuously
improve operational performance;
optimise productivity and utilisation
of existing assets
•Cash generation and debt
reduction: consolidate Brazil after
rapid growth; right-size US for
structural downturn; rationalise non-
core activities and property
•Profitable growth in Brazil
•Optimise US returns
•Higher-value product mix
•Operating leverage
•Margin expansion
•Cash generation
•Debt reduction
•Unlock Group synergies
ArborGen 2026 ASM
FY27 OUTLOOK
For FY27, ArborGen is targeting continued improvement
in revenue, cash generation and debt reduction
•Continued volume growth in Brazil, supported by
increased capacity and ongoing customer transition to
protected clones
•Some revenue and volume growth in the US South,
driven by higher-value products and market share gains
•Further improvements in operational efficiency, cost
management and increasing integration and
collaboration between the US and Brazil
•Continued investment in higher-value and added value
products
ArborGen is entering
FY27 with a stronger
operational platform, a
more resilient business
and clear opportunities
for growth.
The deliberate and
disciplined choices
being made today will
enable the business to
perform well in a more
subdued US market,
while continuing to
grow in Brazil.
ArborGen 2026 ASM
10
POSITIONED TO PERFORM
•Clear strategy
•Market leadership position in target markets - US South and Brazil
•Unparalleled product portfolios in each of our core markets
•Focused on value growth
•Multi-decade investment in research and intellectual property
•Service more than 2,000 customers each year
•Production capacity of ~500 million+ seedlings per annum
ArborGen 2026 ASM
11
Patrick Cumbie
INTERIM CEO
ArborGen 2026 ASM
LEADERSHIP FOCUS 2026
13
Strategic
Priorities
Build sales of high value
products
Expand
margins
Cash generation and
debt reduction
LEADERSHP PRIORITIES
People and CultureStrong management. Committed and passionate team.
Experts in our field. Customer focused.
Genetics LeadershipLeverage our strengths. Invest in product development.
Build market share and leadership.
Operational Excellence Right-size the US. Consolidate Brazil. Improve efficiency and
productivity.
Financial Stability Build a leaner operation that can scale as demand grows.
Maximise the value of investments.
ArborGen 2026 ASM
THE GENETICS DIVIDEND
14
ArborGen 2026 ASM
Superior Trees
Straighter, higher value,
more disease resistance,
increased harvest
Genetically
Improved Seedlings
Offspring with enhanced
traits from seed
orchards
Seed Orchards
Controlled environments
where selected parent
trees produce improved
seeds
Selected Parent
Trees
Superior trees based on
desirable traits
Open Pollinated
Trees
Naturally pollinated with
genetic variability
Genetically
Superior Trees
SMARTER SEEDLINGS. CLEARER CHOICES.
15
ARBORGEN SCORE
OPReliable performance and
balanced return
OP ProImproving productivity
without added cost
MCPBoosting sawtimber potential
and overall value
MCP-
PRO
Maximising growth, quality
and harvest returns
MCP-
PRO +
For top-tier investors seeking
the highest ROI
PRODUCT CATEGORIES
ArborGen 2026 ASM
Volume
Gain
Sawtimber
Potential
Total
Tons/Acre
ArborGen
Score
$/Acre at
Clearcut
50%15%19060
20%
25%
30%
35%
60%
75%
75%
75%
208
216
229
238
$2,348
$2,851
$3,454
$3,808
$4,068
+$500/acre
+$1,100/acre
+$1,500/acre
+$1,700/acre
71
82
96
104
CUSTOMERS ARE REALISING SIGNIFICANT GAINS
•Significant hectares of commercial
MCP plantations are now reaching
mid-rotation ages
•Real-world data is being captured
and customers are seeing solid gains
from MCP
•In some cases we are seeing
plantations on track to produce
100% more sawtimber over OP
genetics
Overall, MCP plantations have larger
volume and better quality than OP
plantations
16
ArborGen 2026 ASM
15202530
50
100
150
200
Age (years)
Total Volume (tons/acre)
Total Volume by Age with Genetic Trends
Genetics
MCP-Pro+
OP
Mean Marginal Product Volume Gains at Age 25 vs OP
50
100
Marginal % Gain
0
Genetics
Product Type
Chip-n-Saw
Pulpwood
Sawtimber
PROTECTED EUCALYPTUS CLONES OFFER EXCEPTIONAL YIELD GAINS
Protected eucalyptus clones offer exceptional yield gains over market clones in Brazil
•We test and evaluate licensed and proprietary genetics for the market across Brazil
•Screened for propagation, growth, wood properties, diseases
•Data and results guide our selection of materials in the market
17
0
10
20
30
40
50
60
70
80
90
Campo
Novo
Parecis -
MT
Ribas do
Rio Pardo
- MS
Nova
Mutum -
MT
Selvíria -
MS
Ribas do
Rio Pardo
- MS
Igreja
Nova - AL
Nova
Mutum -
MT
Ribas do
Rio Pardo
- MS
Bauru -
SP
Bauru -
SP
Borebi -
SP
Nova
Mutum -
MT
Bocaiúva
- MG
Francisco
Dumont -
MG
4,14,44,64,74,85,05,25,35,46,0
A217
AEC0144
GG2808
IPB1
ArborGen 2026 ASM
MARKET OPPORTUNITY
Build scale in Brazil, grow market share in US South
TOTAL MARKET
543M
178M
720M
119M
ADDRESSABLE
MARKET
ARBORGEN
CURRENT
VOLUME
667 MILLION
US SOUTH
(Loblolly Pine)
BRAZIL
Market size and Addressable Market
based on management estimates
and available market information
1.35 BILLION
1.2b Eucalyptus
150m Pine
Number of seedlings
ArborGen 2026 ASM
18
19
SHAREHOLDER DISCUSSION
ArborGen 2026 ASM
RESOLUTIONS
Resolution 1: That the Directors be authorised to fix the fees and
expenses of Grant Thornton as the Company’s auditor
Resolution 2: Re-election of Paul Smart as a Director of the Company
Resolution 3: Re-election of Thomas Avery as a Director of the Company
ArborGen 2026 ASM
20
21
OTHER BUSINESS
CLOSE OF THE MEETING
ArborGen 2026 ASM
22
ADJUSTED US GAAP RECONCILIATION
Fiscal year ending March US $mMar
2026
US GAAP
Revenue68.2
Gross margin (excluding DDA)22.4
LessSG&A (9.6)
LessR&D(2.5)
PlusOther income (expense)1.2
Adjusted US GAAP EBITDA
(3) (4)
11.5
Adjustments
Gain on sale of parcel of land0.2
Gain from ERC credits0.8
US GAAP EBITDA
(1) (2)
12.5
1.Under US GAAP, from a statutory reporting perspective, the classification of the
expense items, and other significant items in this table may differ from what is
presented in the financial statements.
2.US GAAP EBITDA excludes NZ public company costs.
3.Adjusted US GAAP EBITDA excludes one-off and unusual items which may include
restructure costs, impairments and write downs on assets, acquisition/sale
transaction costs and other one-off items. In FY26, one-off and unusual items were
$0.2m gain on sale of a parcel in Texas and an $800k gain for recognising an ERC tax
credit for which statute of limitations for potential audit has passed.
4.The Company uses Adjusted US GAAP EBITDA when discussing financial performance.
This is a non-GAAP financial measure and is not recognised within IFRS. Non-GAAP
financial measures should not be viewed in isolation nor considered as a substitute
for measures reported in accordance with GAAP. Management believes that
Adjusted US GAAP EBITDA provides useful information, as it is used internally to
evaluate performance, and it is also a measure that equity analysts focus on for
comparative company performance purposes, as themeasure removes distortions
caused by differences in asset age, depreciation policies and debt:equity structures.
ArborGen 2026 ASM
23
DISCLAIMER
This presentation has been prepared by ArborGen Holdings Limited (“ArborGen”), to provide an overview of the performance of ArborGen and its activities at the date of this presentation.
It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presentation should be read in conjunction with ArborGen’s interim
and annual reports, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.com/companies/ARB and www.arborgenholdings.com.
The information in this presentation is of a general nature only. It is not a complete description of ArborGen.
This presentation is not a recommendation or offer of financial products for subscription, purchase or sale, or an invitation or solicitation for such offers.
This presentation is not intended as investment, financial or other advice and must not be relied on by any prospective investor. It does not take into account any particular prospective
investor’s objectives, financial situation, circumstances or needs, and does not purport to contain all the information that a prospective investor may require. Any person who is considering
an investment in ArborGen securities should obtain independent professional advice prior to making an investment decision, and should make any investment decision having regard to
that person’s own objectives, financial situation, circumstances and needs.
Past performance information contained in this presentation is not an indication of future performance and should not be relied upon as such. This presentation may also contain forward
looking statements with respect to the financial condition, results of operations and business, and business strategy of ArborGen. Information about the future, by its nature, involves
inherent risks and uncertainties. Accordingly, nothing in this presentation is a promise or representation as to the future or a promise or representation that a transaction or outcome
referred to in this presentation will proceed or occur on the basis described in this presentation. Statements or assumptions in this presentation as to future matters may prove to be
incorrect.
A number of financial measures are used in this presentation and should not be considered in isolation from, or as a substitute for, the information provided in ArborGen’s financial
statements available at www.arborgenholdings.com. This presentation may include non-GAAP financial measures. This information has been included on the basis that ArborGen
management and directors consider that this non-GAAP information assists readers to understand the key drivers of ArborGen’s performance which are not disclosed as GAAP measures in
ArborGen’s financial statements.
ArborGen and its related companies and their respective directors, employees and representatives make no representation or warranty of any nature (including as to accuracy or
completeness) in respect of this presentation and will have no liability (including for negligence) for any errors in or omissions from, or for any loss (whether foreseeable or not) arising in
connection with the use of or reliance on, information in this presentation.
All references to currencies in this document are in US dollars (US$) unless otherwise stated.
ArborGen 2026 ASM
24
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- EBO — EBOS Group Limited: Annual Meeting Presentation2026-10-20
“It also marked an important milestone. Over recent years, the Board has backed a significant program of investment to modernise our network and strengthen our portfolio. That facility investment cycle is now complete. As a result, EBOS goes into FY27 a stronger business. We ha…”
- TWL — TradeWindow Holdings Limited: TWL Annual General Shareholders' Meeting - Presentation2026-09-29
“V I R T U A L M E E T I N G How to participate –asking questions Shareholders and proxyholders can put questions to the board before and during the meeting. Written questions Questions may be submitted ahead of the meeting. During the meeting, select the Q&A tab on the right o…”
- MCY — Mercury NZ Limited: Mercury 2026 Annual Shareholders' Meeting2026-09-18
“2026 ASM – Chair and Chief Executive Addresses | 18 September 2026 | Page 5 of 5 As electricity demand grows, our focus is on bringing forward new renewable generation to support that growth, while continuing to maintain reliable electricity for homes, businesses, and communi…”